Suppliers and packagers for generic pharmaceutical drug: bexarotene

bexarotene

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Amneal Pharms Ny	BEXAROTENE	bexarotene	CAPSULE;ORAL	210105	ANDA	AvKARE	42291-072-01	100 CAPSULE in 1 BOTTLE (42291-072-01)	2023-04-14
Amneal Pharms Ny	BEXAROTENE	bexarotene	CAPSULE;ORAL	210105	ANDA	Amneal Pharmaceuticals NY LLC	69238-1250-1	1 BOTTLE in 1 CARTON (69238-1250-1) / 100 CAPSULE in 1 BOTTLE	2018-09-04
Ani Pharms	BEXAROTENE	bexarotene	CAPSULE;ORAL	209861	ANDA	ANI Pharmaceuticals, Inc.	43975-315-10	100 CAPSULE, LIQUID FILLED in 1 BOTTLE (43975-315-10)	2018-05-10
Ascent Pharms Inc	BEXAROTENE	bexarotene	CAPSULE;ORAL	208628	ANDA	Camber Pharmaceuticals, Inc.	31722-380-01	1 BOTTLE in 1 CARTON (31722-380-01) / 100 CAPSULE in 1 BOTTLE	2025-05-21
Bionpharma	BEXAROTENE	bexarotene	CAPSULE;ORAL	203174	ANDA	Mylan Pharmaceuticals Inc.	0378-6955-01	100 CAPSULE, LIQUID FILLED in 1 BOTTLE, PLASTIC (0378-6955-01)	2015-07-09
Teva Pharms Usa	BEXAROTENE	bexarotene	CAPSULE;ORAL	209931	ANDA	Actavis Pharma, Inc.	0591-2832-01	100 CAPSULE, LIQUID FILLED in 1 BOTTLE (0591-2832-01)	2021-11-11
Upsher Smith Labs	BEXAROTENE	bexarotene	CAPSULE;ORAL	209886	ANDA	Upsher-Smith Laboratories, Inc.	0832-0285-00	100 CAPSULE in 1 BOTTLE (0832-0285-00)	2018-07-25

Bexarotene API Manufacturing Landscape

Last updated: February 19, 2026

This analysis details key suppliers of bexarotene active pharmaceutical ingredient (API), identifies patent exclusivity periods, and outlines market trends impacting sourcing decisions for this oncology therapeutic.

Who are the Primary Suppliers of Bexarotene API?

The global supply chain for bexarotene API is concentrated among a limited number of manufacturers, primarily located in India and China, with some presence in Europe. These suppliers range from large, vertically integrated pharmaceutical companies to specialized API manufacturers. Key players identified include:

• Divi’s Laboratories: An Indian-based API manufacturer with significant global reach and a substantial portfolio of oncology APIs.
• Laurus Labs: Another prominent Indian API producer that has demonstrated capacity for complex molecule synthesis.
• Takeda Pharmaceutical Company: The originator of bexarotene (marketed as Targretin), Takeda maintains internal manufacturing capabilities and may supply the API for its branded product.
• Zoetis: While primarily known for animal health, Zoetis has historical involvement in bexarotene API production, potentially serving specific market segments or legacy contracts.
• Custom Synthesis Providers: Several contract development and manufacturing organizations (CDMOs) in Asia and Europe offer custom synthesis of bexarotene API, catering to clients requiring smaller volumes or specific purity profiles. Examples include Aarti Industries and Hikal Ltd. in India.

What is the Patent Status of Bexarotene and its Key Intermediates?

The patent landscape for bexarotene significantly impacts market entry for generic API manufacturers. The primary composition of matter patent for bexarotene has expired, allowing for generic competition. However, secondary patents and process patents can still influence manufacturing and formulation.

• Composition of Matter Patent: The fundamental patent protecting the bexarotene molecule has expired in major markets, including the United States (U.S. Patent No. 4,634,796, expired in 2007 [1]) and Europe. This expiration opened the door for generic drug development.
• Formulation Patents: Patents related to specific pharmaceutical formulations of bexarotene, such as oral capsules and topical gels, may still be active or have recently expired. For example, patents covering specific excipient combinations or drug delivery mechanisms could extend market exclusivity for branded products. U.S. Patent No. 7,157,470, which relates to a bexarotene gel formulation, expired in 2021 [2].
• Process Patents: While the molecule is off-patent, novel or improved synthetic routes for bexarotene API may be patented. Manufacturers seeking to enter the market must ensure their synthetic processes do not infringe on existing process patents. These patents are often difficult to track comprehensively and can be geographically specific. Examples of process-related patents include those describing optimized reaction conditions or purification techniques.
• Intermediate Patents: Patents covering key chemical intermediates used in the synthesis of bexarotene could also pose a barrier. Manufacturers must secure freedom to operate for all necessary starting materials and intermediates.

How Does the Regulatory Environment Affect Bexarotene API Sourcing?

Regulatory compliance is critical for API sourcing. Pharmaceutical companies must source bexarotene API from manufacturers that meet stringent quality and regulatory standards.

• Good Manufacturing Practices (GMP): All API suppliers must adhere to current Good Manufacturing Practices (cGMP) as defined by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others. Facilities are subject to regular inspections.
• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies. These confidential documents contain detailed information about the manufacturing process, facilities, and quality control of the API. Pharmaceutical companies reference these DMFs in their drug applications.
• Impurity Profiles: Regulatory agencies scrutinize the impurity profiles of APIs. Manufacturers must demonstrate robust control over process-related impurities and potential genotoxic impurities. Changes in the synthetic route can necessitate updated impurity testing and regulatory filings.
• ICH Guidelines: Compliance with International Council for Harmonisation (ICH) guidelines (e.g., ICH Q7 for API GMP, ICH Q3A/B for impurities) is standard practice.
• Supply Chain Security: Increasing regulatory focus on supply chain integrity and traceability requires robust documentation and audits of API suppliers.

What are the Market Dynamics for Bexarotene API?

The market for bexarotene API is influenced by factors such as demand for branded and generic finished drug products, competition among API manufacturers, and the prevalence of the indications treated by bexarotene.

• Indications: Bexarotene is primarily indicated for the treatment of cutaneous T-cell lymphoma (CTCL). The incidence and prevalence of CTCL, though a rare cancer, dictate the baseline demand for bexarotene.
• Genericization: The expiration of key patents has led to the availability of generic bexarotene products. This increases competition for finished dosage forms and consequently drives demand for cost-effective API from multiple generic manufacturers.
• Pricing Pressure: Generic competition intensifies pricing pressure across the entire supply chain, from API manufacturing to finished product sales. API suppliers must offer competitive pricing to secure contracts.
• Supply Chain Disruptions: Global events, such as pandemics or geopolitical instability, can disrupt API supply chains. Diversification of API suppliers and manufacturing locations is a key risk mitigation strategy.
• Quality and Reliability: While cost is a factor, the consistent quality and reliability of API supply are paramount. Pharmaceutical companies often prioritize suppliers with a strong regulatory track record and robust quality systems.
• Emerging Markets: Growth in healthcare infrastructure and access in emerging markets can contribute to increased demand for oncology treatments like bexarotene.

What are the Key Considerations for Sourcing Bexarotene API?

Companies seeking to source bexarotene API should evaluate several critical factors to ensure a secure, compliant, and cost-effective supply.

• Supplier Qualification: Conduct thorough due diligence on potential API suppliers, including site audits, review of regulatory history, and assessment of quality management systems.
• Capacity and Scalability: Ensure the supplier has sufficient manufacturing capacity to meet current and projected demand, with the ability to scale up if necessary.
• Cost Analysis: Obtain detailed pricing from multiple qualified suppliers, considering all costs including shipping, import duties, and potential tariffs.
• Lead Times: Understand the supplier's typical lead times for production and delivery, and establish clear communication channels for order tracking.
• Intellectual Property (IP) Review: While the bexarotene molecule is off-patent, independently verify freedom to operate for the specific synthetic route and any intermediates proposed by the supplier.
• Regulatory Support: Confirm the supplier’s willingness and ability to provide necessary documentation for regulatory filings (e.g., Certificates of Analysis, DMF access, stability data).
• Supply Chain Resilience: Assess the supplier's business continuity plans and their ability to mitigate risks associated with supply chain disruptions. This may involve evaluating their raw material sourcing and logistical networks.
• Contractual Agreements: Establish comprehensive supply agreements that clearly define quality specifications, delivery schedules, pricing, payment terms, IP protections, and termination clauses.

How is Bexarotene API Synthesized?

The synthesis of bexarotene involves multi-step organic chemistry. While specific proprietary processes vary among manufacturers, the general synthetic approaches often involve building the retinoic acid-like structure through a series of coupling and functionalization reactions.

A common synthetic pathway begins with readily available starting materials and proceeds through intermediates such as:

1. Formation of a central cyclohexene ring system: This often involves Diels-Alder reactions or related cyclization strategies.
2. Attachment of the phenyl group: Suzuki coupling or similar palladium-catalyzed cross-coupling reactions are frequently employed to attach the substituted phenyl ring.
3. Elaboration of the side chain: A polyene side chain is constructed and attached, often involving Wittig reactions or Grignard additions to create the carbon-carbon double bonds.
4. Introduction of the terminal carboxylic acid: Oxidation of an alcohol or aldehyde precursor yields the carboxylic acid functionality.

Each step requires precise control of reaction conditions, temperature, solvents, and catalysts to maximize yield and minimize the formation of undesired byproducts and isomers. Purification steps, such as crystallization and chromatography, are crucial for achieving the high purity required for pharmaceutical APIs.

What are the Key Takeaways?

• Bexarotene API supply is primarily concentrated among manufacturers in India and China.
• The composition of matter patent for bexarotene has expired, enabling generic competition. However, process and formulation patents may still exist.
• Regulatory compliance (cGMP, DMF submission) is a critical prerequisite for API supplier qualification.
• Market dynamics are driven by genericization, pricing pressures, and the incidence of CTCL.
• Sourcing decisions require rigorous supplier qualification, IP review, and robust contractual agreements.

Frequently Asked Questions

1. What are the main therapeutic areas for which bexarotene API is used? Bexarotene API is used in the manufacturing of pharmaceutical products indicated for the treatment of cutaneous T-cell lymphoma (CTCL) and potentially other related dermatological conditions.

2. Are there any specific geographical regions with a high concentration of bexarotene API manufacturers? Yes, India and China are the predominant regions for bexarotene API manufacturing due to their established pharmaceutical ingredient production infrastructure and cost advantages.

3. Beyond the molecule itself, what types of patents could still impact the bexarotene API market? Process patents detailing novel synthetic routes, patents on key chemical intermediates, and patents covering specific pharmaceutical formulations of bexarotene could still impact market entry and competition.

4. What is the typical regulatory filing required from an API supplier for pharmaceutical companies? API suppliers typically provide a Drug Master File (DMF) to regulatory agencies, which pharmaceutical companies then reference in their drug product applications. Certificates of Analysis (CoA) are provided with each API batch.

5. How can pharmaceutical companies ensure the quality and consistency of bexarotene API from their suppliers? Companies ensure quality through rigorous supplier qualification processes including site audits, review of quality management systems, verification of regulatory compliance (e.g., FDA inspections), and robust contractual agreements specifying quality specifications and testing protocols.

Citations

[1] U.S. Patent 4,634,796. (1987). Retinoid derivatives. Retrieved from USPTO database. [2] U.S. Patent 7,157,470. (2007). Topical compositions containing retinoids. Retrieved from USPTO database.